Abstract:Background:Bone marrow-derived mesenchymal stem cells (MSCs) have been proved in vitro to inducible differentiate into many kinds of cells of mesenchymal tissues such as osteocytes,chondrocytes, adipocytes,myocytes et al,especially myocardium cells. Recently it was shown that the wall thickness and heart function were improved after MSCs implantation in animal experiments and large-scale clinical trials. But other studies didn’t show that grafted stem cells can bring benefits to heart function in patients with cardiac disease. These therapeutic differences may be rise at least because of lack of visible method to trace in vivo grafted stem cells bio-behaviors such as survive,proliferation,distribution and differentiation. In recent decade an in vivo cellular tracking techniques by using luciferase marker so called BLU have been developed for long-term study of stem cells homing and migration. Bioluminescent imaging ( BLU) technology is a technology to integrate exogenous report luciferase genes into host cells,and express luciferase. This enzyme will give out the visible light when it reacts with its substrate fluorescein under the condition of existing O2 and ATP,to track living cells in real time. In BLU technology the vector for gene transfection is considered a principal because it very closely links to gene transfection efficiency and hence cells lumination. Objective:By using reconstructed-lentivirus vector transfection and bioluminescent imaging techniques to monitor in vivo survival and proliferation and migration of grafted human mesenchymal stem cells (hMSCs) in mice. Methods:Firefly-Luciferase (LUC) -Lentivirus vector were constructed and co-cultured with hMSCs in vitro. Then transfected hMSCs were subcutaneously injected into mice. Either in vitro and in vivo biophotonic imaging of hMSCs were detected by using Xenogen Visible System. Results:1. When multiplicity of infection (MOI) was 100,transfection efficiency of LUC-lentivirus vector could come to (29. 6 ±1. 5)%. Transfected- hMSCs had expressed LUC after 20 successive generation. Indicating this reconstructed lentivirus-LUC-vector has the characteristics of high transfection sensitivity to hMSCs,and high stability for exogenous reporter gene integration and its expression. 2. No morphological and proliferation effect on hMSCs were observed after co- culture with constructed lentivirus vector for 20 generation. This demonstrating that neither lentivirus vector nor exogenous reporter gene has cytotoxicity to targeting cells. 3. Detected in vivo bioluminescence intensity was positively correlated with grafted mass of transfected-LUC hMSCs ( R2 = 0. 9826 ). 4. Since cellular transplantation,in vivo bioluminescence signal bounded injection location were detectable and the signal intensity were linear faded out until to 6th day. Means the survival,homing,proliferation and migration of Firefly-Luciferase gene transfected hMSCs can be quantitatively in vivo monitored in real time. Conclusion: Reconstructed descytotoxicityly lentivirus vector is an effective and safety tool for Firefly-Luciferase gene integrating into hMSCs. Thus by using bioluminescent tracer techniques the phenotype and potential involving homing,proliferation and migration of LUC-transfectied hMSCs can be quantitatively in vivo real-timely monitored.

Dynamic tracking of human umbilical cord mesenchymal stem cells (hUC-MSCs) following intravenous administration in mice model

Umbilical cord-derived mesenchymal stem cell therapy for neurological disorders via inhibition of mitogen-activated protein kinase pathway-mediated apoptosis.

Bio-distribution and toxicity potential of human umbilical cord mesenchymal stem cells in cynomolgus monkeys

Preclinical assessments of safety and tumorigenicity of very high doses of allogeneic human umbilical cord mesenchymal stem cells

hUC-MSCs: evaluation of acute and long-term routine toxicity testing in mice and rats

Tracking of transplanted human umbilical cord-derived mesenchymal stem cells labeled with fluorescent probe in a mouse model of acute lung injury

GFP Labeling and Hepatic Differentiation Potential of Human Placenta-Derived Mesenchymal Stem Cells

Ex Vivo Expansion and Transplantation of Hematopoietic Stem/progenitor Cells Supported by Mesenchymal Stem Cells from Human Umbilical Cord Blood.

In Vivo Monitoring of Hmscs Stem Cell by Bioluminescent Tracer in Mice

A multi-modality imaging strategy to determine the multiple in vivo fates of human umbilical cord mesenchymal stem cells at different periods of acute liver injury treatment

Repeat-dose toxicity study of human umbilical cord mesenchymal stem cells in cynomolgus monkeys by intravenous and subcutaneous injection

Lack of tumorigenesis and protumorigenic activity of human umbilical cord mesenchymal stem cells in NOD SCID mice

The Experimental Investigation of Glioma ⁃trophic Capacity of Human Umbilical Cord-Derived Mesenchymal Stem Cells after Intraventricular Administration

In vivo hepatic differentiation of mesenchymal stem cells from human umbilical cord blood after transplantation into mice with liver injury.

Human Umbilical Cord Mesenchymal Stem Cells Toxicity and Allergy Effects: in Vivo Assessment

Characterization of dynamical changes in vital signs during allogeneic human umbilical cord-derived mesenchymal stem cells infusion

Study on Preclinical Safety and Toxic Mechanism of Human Umbilical Cord Mesenchymal Stem Cells in F344RG Rats

Human umbilical cord mesenchymal stem cells and derived hepatocyte-like cells exhibit similar therapeutic effects on an acute liver failure mouse model.

Optimization of Mesenchymal Stem Cells (MSCs) Delivery Dose and Route in Mice with Acute Liver Injury by Bioluminescence Imaging

Encapsulation of Human Umbilical Cord Mesenchymal Stem Cells in LunaGel Photocrosslinkable Extracellular Matrix and Subcutaneous Transplantation in Mice

Ultrasensitive in Vivo Fluorescence Imaging of Mesenchymal Stem Cells and Small Molecule-Induced Pluripotent Stem Cells in BALB/c mice.